LIBTAYO may help
shrink tumors.

LIBTAYO was studied in a clinical
trial which included patients with
locally advanced BCC after they
were treated with an HHI.

In the trial, 24 out of 84 patients (29%) saw an improvement in their locally advanced BCC with LIBTAYO. These patients had responses that lasted between 2.1 months and 21.4+ months; plus sign [+] means this patient was still responding to treatment at their last assessment.

What is locally advanced BCC?

Learn more about how BCC can progress to locally advanced disease.